Table 2.

Association results for nine previously reported pancreatic cancer susceptibility loci and current PACGENE data

PublishedfPACGENEg
Chromosomea SNPb genec positiondStudyeOR (95% CI)PMAF (cases; controls)OR (95% CI)PNhMAFf (cases; controls)
9q34.3 rs505922(C/T) ABO 136,149,229PanScan I (17)1.20 (1.12–1.28)5.37 × 10−80.39;0.351.29 (1.12–1.48)4.37 × 10−4903 cases, 847 controls0.40; 0.342
13q21.32 rs9543325(C/T) KLF5 73,916,628PanScan II (18)1.26 (1.18–1.35)3.27 × 10−110.42;0.371.25 (1.08–1.45)3.58 × 10−3863 cases, 707 controls0.44;0.38
1q32.1 rs3790844(C/T) NR5A2 200,007,432PanScan II (18)0.77 (0.71–0.84)2.45 × 10−100.20;0.240.87 (0.73–1.03)9.48 × 10−2863 cases, 707 controls0.22;0.25
5p15.33 rs401681(T/C) CLPTM1L 1,322,087PanScan II (18)1.19 (1.11–1.27)3.66 × 10−70.49;0.451.31 (1.14–1.52)2.26 × 10−4863 cases, 707 controls0.50;0.43
7q32.3 rs6971499(C/T) LINC-PINT 130,680,521PanScan III (19)0.79 (0.74–0.84)2.98 × 10−120.12;0.150.72 (0.58–0.88)1.73 × 10−3803 cases, 693 controls0.12;0.16
13q12.12 rs9581943(A/G) PDX1-AS1 28,493,997PanScan III (19)1.15 (1.10–1.20)2.35 × 10−90.43;0.411.11 (0.96–1.29)1.50 × 10−1803 cases, 693 controls0.42;0.40
2p13.3 rs1486134(G/T) ETAA1 67,639,769PanC4 (20)1.14 (1.09- 1.19)3.36 × 10−90.30;0.281.36 (1.13–1.63)9.88 × 10−4564 cases, 606 controls0.31; 0.26
7p13 rs17688601(A/C) SUGCT 40,866,663PanC4 (20)0.88 (0.84–0.92)1.41 × 10−80.24;0.270.77 (0.64–0.94)1.05 × 10−2564 cases, 606 controls0.22;0.28
3q29 rs9854771 (A/G) TP63 189,508,471PanC4 (20)0.89 (0.85–0.92)2.35 × 10−80.33;0.360.92 (0.77–1.09)3.14 × 10−1564 cases, 606 controls0.33;0.35
  • Abbreviation: MAF, minor allele frequency.

  • aCytogenetic region according to NCBI genome build 37 and NCBI's Map Viewer.

  • bEffect allele/reference allele.

  • cThe closest RefSeq gene.

  • dSNP position according to NCBI genome build 37 (Hg19).

  • eThe study where the association was originally identified and published.

  • fThe OR and P value reported in the publication referred to in the “Study” column.

  • gThe OR and P value observed in the PACGENE study.

  • hThe number of individuals included for each association test. As individuals that were present in PACGENE and the prior studies were removed, the number of individuals analyzed varies.